This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: August 31, 2005
Last updated: June 1, 2007
Last verified: June 2007
The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.

Condition Intervention Phase
Smoking Cessation Drug: varenicline (CP-526,555) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Continuous abstinence Weeks 13 -24.

Secondary Outcome Measures:
  • Continuous abstinence Weeks 13-52
  • Long term quit rate at Week 52
  • 7-day Point Prevalence of abstinence at Weeks 24, 52
  • 4-week Point Prevalence of abstinence at Week 52
  • Time to first cigarette post randomization

Estimated Enrollment: 2000
Study Start Date: April 2003
Study Completion Date: March 2005

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion Criteria:

  • Subjects with clinically significant cardiovascular disease in the past 6 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00143286

  Hide Study Locations
United States, California
Pfizer Investigational Site
Santa Ana, California, United States
United States, Florida
Pfizer Investigational Site
West Palm Beach, Florida, United States
United States, Kentucky
Pfizer Investigational Site
Lexington, Kentucky, United States
United States, Ohio
Pfizer Investigational Site
Mogadore, Ohio, United States
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States
United States, Washington
Pfizer Investigational Site
Seattle, Washington, United States
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada
Canada, Nova Scotia
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Canada, Prince Edward Island
Pfizer Investigational Site
Cornwall, Prince Edward Island, Canada
Canada, Quebec
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Czech Republic
Pfizer Investigational Site
Prague 2, Czech Republic
Pfizer Investigational Site
Hellerup, Copenhagen, Denmark
Pfizer Investigational Site
Aarhus C, Denmark
Pfizer Investigational Site
Frederikssund, Denmark
Pfizer Investigational Site
Bergen, Norway
Pfizer Investigational Site
Honefoss, Norway
Pfizer Investigational Site
Oslo, Norway
Pfizer Investigational Site
Göteborg, Sweden
Pfizer Investigational Site
Helsingborg, Sweden
Pfizer Investigational Site
Stockholm, Sweden
United Kingdom
Pfizer Investigational Site
London, Surrey, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00143286     History of Changes
Other Study ID Numbers: A3051035
Study First Received: August 31, 2005
Last Updated: June 1, 2007

Additional relevant MeSH terms:
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on September 21, 2017